HCVguidelines.org, a website developed by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) to provide up-to-date guidance on the treatment of hepatitis C (HCV) has updated several sections of the website based on newly available therapies and data.
The latest version of the HCV Guidance provides new recommendations regarding the optimal use of antiviral agents for hepatitis C in the wake of the approval by the Food and Drug Administration of sofosbuvir/velpatasvir. It also integrates recent trial data for other combinations of direct-acting antiviral agents, particularly in unique groups of patients, including those who have impaired kidney function, have undergone liver transplantation, or have HIV co-infection.
“We believe that the updated recommendations will help caregivers with regimen choice not only in common treatment scenarios, but will also importantly provide guidance in cases where randomized trial data or specific FDA labeling may be lacking,” said Raymond Chung, MD, co-chair of the guidance panel.
“The latest updates to HCVguidelines.org bring a trusted document up to date with the latest therapeutic options. The guidance now offers more than one front-line regimen for each viral genotype and updates recommendations for patients of high complexity. Most treating clinicians will find workable treatment options for the majority of their patients,” said Hugo Vargas, MD, guidance panel co-chair.
The update also offers guidance regarding the prudent use of HCV resistance testing, a source of considerable confusion for practitioners. Important information regarding the monitoring of patients with cirrhosis who are undergoing therapy with direct acting antivirals is also provided. Tables highlighting important potential drug-drug interactions between HCV antivirals and commonly prescribed medications, including antiretroviral and antirejection agents, have also been updated.
“As more patients gain coverage for curative therapies, our panel hopes that the updated guidance allows more providers to join the fight against this deadly and expanding epidemic,” said Arthur Kim, MD, guidance panel co-chair.
for updates regarding the release of this and other sections of the guidance.
< Previous Article | Next Article >